Markets

Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% - Tale of the Tape

Orexigen Therapeutics, Inc. ( OREX ) saw a big move in the last trading session, as the company's shares fell by nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent uptrend for OREX, as the stock is up nearly 7% in the past one-month time frame.

The biopharmaceutical company has not seen any estimate revision over the past month, and the current year earnings consensus hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, especially on earnings estimates following the recent slump.

OREX currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is positive.

Investors interested in the Drugs industry may consider better-ranked stocks like ANI Pharmaceuticals, Inc. ( ANIP ), Gilead Sciences Inc. ( GILD ) and Osiris Therapeutics, Inc. ( OSIR ), each of which holds a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OREXIGEN THERAP (OREX): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More